Close Menu

Greg Hermanson, Stephen Lee, Mihail Lungu, Dominick Pucci, Robert Suva, Alan Thomson, and Mehmet Toner

Jan 05, 2017

Daktari Diagnostics has formed a scientific advisory board comprising Greg Hermanson, Stephen Lee, Mihail Lungu, Dominick Pucci, Robert Suva, Alan Thomson, and Mehmet Toner.

Hermanson is the chief technology officer and principal at Aurora Microarray-Solutions and president of Greg T. Hermanson bioscience consulting firm. Lee was previously the CSO at OraSure and vice president of R&D at Ortho-Clinical Diagnostics.

Lungu was a senior executive at Boehringer Mannheim, now Roche Diagnostics, while Pucci was an R&D director at Abbott Diagnostics. Suva previously was division vice president of technology futures at IDEXX Laboratories and a senior scientist at SRI International.

Thomson is the technical director at Relitect, and Toner is the Helen Andrus Benedict professor of surgery (bioengineering) at Massachusetts General Hospital, Harvard Medical School. He is also the founding director of the National Institutes of Health BioMEMS Resource Center. 

More Like This

Oct 10, 2019

Stilla Technologies: Ruth Szebries

Stilla Technologies has appointed Ruth Szebries as general manager and vice president of commercial operations for its newly established US subsidiary in Beverly, Massachusetts. Szebries will oversee operations in the Americas for the Paris, France-based digital PCR developer. Her previous life science industry experience includes positions at Applied Biosystems and Beckman Coulter, leading the US subsidiaries of BGI and Exiqon, and serving for three years at Qiagen, most recently as that firm's senior director for global market development.

Oct 09, 2019

First Light Diagnostics: Angela Caliendo

First Light Diagnostics has added Angela Caliendo to its clinical advisory board. She is an editor at the Journal of Clinical Microbiology, a board member and fellow of the Infectious Diseases Society of America, and a fellow at the American Academy of Microbiology. She currently is a professor and the executive vice chair of the department of medicine at the Warren Alpert Medical School of Brown University. 

Oct 09, 2019

VolitionRx: Phillip Barnes

VolitionRx has appointed Phillip Barnes to its board, replacing Habib Skaff, who resigned effective Oct. 9. Barnes is a British physician and has been a clinician and clinical manager with the UK National Health Service and related academic institutions. 

Oct 08, 2019

Biodesix: James Jett

Biodesix has appointed James Jett as chief medical officer. Jett previously served as CMO at Oncoimmune. Before Onocimmune, Jett worked as a professor of medicine at the Mayo Medical School and the University of Pittsburgh. Jett has also served as a consultant for the National Cancer Institute and as the editor in chief of the Journal of Thoracic Oncology from 2006 to 2013. 

Oct 04, 2019

Meridian Bioscience: Bryan Baldasare

Meridian has appointed Bryan Baldasare to chief financial officer. He was previously the interim CFO, corporate controller, and treasurer and is currently also the executive vice president and chief accounting officer. Baldasare has been with Meridian since 2000, and before that he was a senior audit manager at Arthur Andersen LLP. 

Sep 30, 2019

Sebia: David Martyr, Benoît Adelus

Sebia has appointed David Martyr as chairman of its board of directors. Alongside Jean-Marc Chermette, CEO of Sebia, Martyr will support the firm's strategic vision in its ongoing next stage of growth, the firm said.

Martyr has served as member of the board of ALDA, the Analytical, Life Sciences & Diagnostics Association, for the past 6 years and is currently a member of the advisory group of Novo Holdings. He was CEO of Tecan from 2012 to 2019. Prior to joining Tecan, Martyr held various executive roles at Leica Microsystems, including group president from 2007 until 2011. He was vice president and group executive of Danaher from 2009 until 2011.

Benoît Adelus is stepping down at Sebia, after serving as CEO from 2008 to 2017 and chairman since 2017.

Sep 26, 2019

Becton Dickinson: Vincent Forlenza, Thomas Polen

Becton Dickinson announced that Vincent Forlenza will retire from his position as of Jan. 28, 2020. Forlenza, who has been with BD for 40 years and has led the company as CEO since 2011, will continue to serve as executive chairman of its board of directors. Thomas Polen, the firm's chief operating officer, will take over as CEO. 

Sep 26, 2019

Cofactor Genomics: Natalie LaFranzo

Cofactor Genomics has promoted Natalie LaFranzo to Vice President of Market Development. She has been with the company for three years. Previously, she held roles in product management at Horizon Discovery and in marketing and communications at Red Rock Labs. LaFranzo will also head Cofactor's new predictive immune modeling center in Cambridge, Massachusetts. The facility will be the company's hub for the research and operations team working with Boston-based pharma, RNA, precision medicine, and immunotherapy companies. 

Sep 26, 2019

Sight Diagnostics: Assi Gol, Noga Eshed-Baror

Sight Diagnostics has appointed Assi Gol as its chief commercial officer and Noga Eshed-Baror as its general US manager.

Before joining the executive team, Gol served on Sight’s advisory board and has supported the company since its founding in 2011. Previously, he served as the data intelligence director at Shop Direct, an online retailer in the UK. He also spent seven years at McKinsey & Company in London and Tel-Aviv.

Eshed-Baror will lead Sight's US efforts, including commercialization and hiring. He is a graduate of the Stanford Business School and brings more than 10 years of business experience, having led projects at both Google and McKinsey. 

Sep 25, 2019

Myriad Genetics: Colleen Reitan, Lee Newcomer

Myriad Genetics has elected Colleen Reitan and Lee Newcomer to its board of directors.

Reitan has spent more than 32 years working in the Blue Cross Blue Shield system, most recently as president of plan operations for Health Care Service Corporation (HCSC), a health plan covering 16 million lives. Prior to BCBS, Reitan held several roles of increasing responsibility including executive VP and chief operating officer for HCSC and president and chief operating officer of BCBS of Minnesota. She currently serves on the boards of Alnylam Pharmaceuticals and Cricket Health.

Newcomer is a board-certified oncologist who most recently served as senior VP of oncology and genetics for UnitedHealthcare. Previously, he was chief medical officer and senior VP of health policy and strategy at UnitedHealth Group. He also served as chief medical officer at Vivius. Newcomer currently serves on the board of Cellworks Group and Intervention Insights.

Sep 25, 2019

First Light Diagnostics: Joanne Spadoro

Joanne Spadoro has joined First Light Diagnostics as vice president of R&D and regulatory affairs. Spadoro has more than 20 years of experience in the in vitro diagnostics space, the Chelmsford, Massachusetts-based company said. According to her LinkedIn profile, she was chief commercial officer at T2 Biosystems, CSO and VP of worldwide operations at Immucor, and senior VP of global development and operations at Roche Molecular Systems. 

Sep 23, 2019

Illumina: Joydeep Goswami

Illumina has appointed Joydeep Goswami as senior VP of corporate development and strategic planning. Reporting to CEO Francis de Souza, he will be responsible for planning, strategic partnerships and acquisitions.

Goswami brings more than 20 years' experience in new product development, partnerships, licensing, and mergers and acquisitions. He comes to Illumina from Thermo Fisher Scientific, where he was president of the clinical next-generation sequencing and oncology business unit. He has also held leadership positions at Life Technologies and Invitrogen. He holds a doctorate in chemical engineering and an MBA from the Massachusetts Institute of Technology.

Sep 19, 2019

Sophia Genetics: Gaëtan Fraikin, Sergei Yakneen

Sophia Genetics has hired Gaëtan Fraikin as chief marketing officer and Sergei Yakneen as chief information officer. Fraikin joins the Swiss company after short stints with Addictive, Roche, and Illumina, plus 14 years as a marketing agency executive. Yakneen is a former technical officer with the European Molecular Biology Laboratory and led the technical working group of the Pan Cancer Analysis of Whole Genomes project for the Ontario Institute for Cancer Research. 

Sep 18, 2019

Fred Hutchinson Cancer Research Center: Gary Gilliland

The Fred Hutchinson Cancer Research Center announced that D. Gary Gilliland plans to step down as president and director in 2020. Prior to working at the Hutch, Gilliland served as director of the leukemia program at Dana-Farber/Harvard Cancer, senior VP and global oncology franchise head at Merck, and vice dean and VP of precision medicine at Perelman School of Medicine at the University of Pennsylvania. 

Sep 17, 2019

Ontera: Mark Rose and Raparti Swayambhu

Nanopore diagnostics firm Ontera has appointed Mark Rose as VP of product management and Raparti Swayambhu as VP of software.

Rose will be responsible for development, launch, and commercial activities of the firm's diagnostic product portfolio. He comes from Google, where he was a product lead and helped launch the Nest brand of internet-connected devices for the home. He has also worked at Motorola and Facebook. He holds an MBA from the Craig School of Business at California State University, Fresno.

Swayambhu will oversee the firm's software development, enterprise IT, and data science teams. He brings more than 20 years of experience in software development and has held technical leadership roles at Sema4 and Genentech, among other firms. He holds a master's degree in computer science from Carnegie Mellon University.